MELISSA HALE: Open Payments
NPI 1285117044 · RICHMOND, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$667 in 32 payments from 11 companies in 2025. Trend: 2023 $350 · 2024 $879 · 2025 $667
Food & beverage: $667
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 9 | $217 |
| Teva Pharmaceuticals USA, Inc. | 5 | $87 |
| Collegium Pharmaceutical, Inc. | 3 | $74 |
| Vanda Pharmaceuticals Inc. | 3 | $63 |
| Lundbeck LLC | 3 | $59 |
| Neurocrine BioSciences, Inc. | 2 | $51 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $40 |
| Tris Pharma Inc | 2 | $29 |
| Neos Therapeutics, LP | 1 | $17 |
| Supernus Pharmaceuticals, Inc. | 1 | $16 |
Products named: VRAYLAR, Jornay PM, AUSTEDO XR, FANAPT, REXULTI, INGREZZA, CAPLYTA, Dyanavel XR.
Industry payments across VA — which companies pay providers there.
